3Chevalier T LE, Berthau P, Ruffle P. NVB and high-dose DDP in advanced non-small cell lung cancer (NSCLC): Result of phase Ⅰ～Ⅱ study and design of multicentric randomized phase Ⅲ study[J].J Cancer Res Clin Oncol, 1990, 116 (suppl part Ⅱ):1052 ～ 1056
4Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial[J]. Ann Oncol, 1994, 5(1): 37～42
5Queiber W, Doss A. Safety and tolerance of Navelbine[J]. J Cancer Res Clin Oncol, 1990, 116(suppl part Ⅱ): 1051～1052
4Chevalier T LE,Berthau P. NVB and high-dose DDP in advanced non-small cell lung cancer (NSCLC): Result of phase I、II study and design of multicentric randomized phase III study [J].J Cancer Res Clin Oncol ,1990,116(Suppl II ): 1052
5Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy innon-small-cell lung cancer,a meta-analysis using updated data on individual patients from 52 randnmized clinical trials. British Medical Journal . 1995
6American Society of Clinical Ontology(ASCO).Clinicalpractice guidelines for the treatment of unresectable non-small-cell lung can- cer. Journal of Clinical Oncology . 1997
7Maher AR, Miake-Lye IM, Beroes J M, et a l. Treatment of metastatic non-small cell lung cancer: a systematic review of comparative effectiveness and cost-effectiveness. Washington (DC): Department of Veterans Affairs (US); 2012: 10-49.
8Boni C, Zanelli F. Ifosfamide in non-small cell lung cancer. Oncology, 2003, 65(Suppl 2): 50-54.
9Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 2012, 13(5): 528-538.
10Drinkard LC, Hoffman PC, Saumuels BL, et al. Dose intensification- a phase I study of ifosfamide with vinorelbine (Navelbine)-rationale and study design in advanced nonsmall cell lung cancer. Semin Oncol, 1995, 22(2): 30-37.
